COMP <GO>
MGX vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Metagenomi Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MGX 0
— ABBV 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $0.83 (+1.03%) • MKT CAP: $31.4M
roic
-35.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MGX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -51.80% | 8.60% | -60.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 7/9 | -6.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 65.1 | -34.15 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $31.4M | $513.86B | -$513.83B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MGX REV | ABBV REV | MGX GROSS % | ABBV GROSS % | MGX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.2M | $61.16B | — | 70.2% | -$89.5M | $17.82B |
| FY 2024 | $52.3M | $56.33B | — | 70.0% | -$112.2M | $17.83B |
| FY 2023 | $44.8M | $54.32B | — | — | -$91.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGX // BETA —
ABBV // BETA 1.15